放疗对接受PD-1免疫检查点抑制剂治疗的转移性癌症患者淋巴细胞计数和生存的影响
该研究纳入5个放射肿瘤中心的110例接受姑息性放疗及帕博利珠单抗或纳武利尤单抗治疗的转移性非小细胞肺癌、黑色素瘤和肾细胞癌患者,共接受225程姑息性放疗。放疗后绝对淋巴细胞计数中位下降161个细胞/mL,颅外放疗和大于5分次的放疗与放疗结束时严重淋巴细胞减少(ALC<500)的 odds 增加相关,而免疫治疗开始时严重淋巴细胞减少与死亡率增加相关(HR 2.1)。
要点
- 姑息性放疗后绝对淋巴细胞计数中位下降161个细胞/mL。
- 颅外放疗和大于5分次的放疗与放疗结束时严重淋巴细胞减少(ALC<500)的 odds 增加相关(OR分别为3.7和3.9)。
- 免疫治疗开始时严重淋巴细胞减少与死亡率增加相关(HR 2.1,P=0.03)。
核心结论
- 颅外或长疗程放疗增加严重淋巴细胞减少的风险,而严重淋巴细胞减少与接受免疫检查点抑制剂治疗患者的较差生存相关。
研究设计与样本
- 从5个放射肿瘤中心识别接受姑息性放疗和帕博利珠单抗或纳武利尤单抗治疗的转移性非小细胞肺癌、转移性黑色素瘤和肾细胞癌患者,排除接受 intervening 细胞毒性化疗的患者。
- 共110例患者接受225程姑息性放疗。
- 记录姑息性放疗前后及免疫检查点抑制剂开始时的绝对淋巴细胞计数和中性粒细胞与淋巴细胞比值。
- 采用Kaplan-Meier法和Cox比例风险模型分析生存。
主要发现
- 放疗后绝对淋巴细胞计数中位变化为-161个细胞/mL。
- 脊柱、肺/纵隔和胸壁放疗后绝对淋巴细胞计数下降大于脑、肢体或腹部/盆腔放疗(P=0.002),且大于5分次放疗后下降更大(P=0.003)。
- 颅外放疗与放疗结束时严重淋巴细胞减少(ALC<500)的 odds 增加相关(OR 3.7;P=0.001),大于5分次放疗亦相关(OR 3.9;P=0.001)。
- 发生放疗诱导的严重淋巴细胞减少的患者在免疫检查点抑制剂开始时更可能出现严重淋巴细胞减少(OR 6.4;P=0.0001),尤其在既往3个月内接受放疗时(OR 189;P<0.0001)。
- 多变量分析显示,免疫检查点抑制剂治疗开始时严重淋巴细胞减少与死亡率增加相关(HR 2.1;P=0.03)。
关键数值与推荐
- 严重淋巴细胞减少定义为绝对淋巴细胞计数<500。
- 放疗后绝对淋巴细胞计数中位变化为-161个细胞/mL。
- 颅外放疗与放疗结束时严重淋巴细胞减少的 OR 为3.7(P=0.001),大于5分次放疗的 OR 为3.9(P=0.001)。
- 放疗诱导的严重淋巴细胞减少与免疫检查点抑制剂开始时严重淋巴细胞减少的 OR 为6.4(P=0.0001),既往3个月内放疗时 OR 为189(P<0.0001)。
- 免疫检查点抑制剂开始时严重淋巴细胞减少与死亡率增加的 HR 为2.1(P=0.03)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Therapeutic radiation has conflicting immune effects: radiation therapy (RT)-induced immunogenic cell death can contribute to immune response, but lymphocytes are also sensitive to RT. It is unknown whether palliative RT leads to lymphopenia in patients treated with immune checkpoint inhibitors (ICIs) and whether this affects outcomes. As such, we sought to assess the impact of palliative RT on circulating lymphocyte count and neutrophil-to-lymphocyte ratio in patients being treated with PD-1-directed ICI and associations with survival. METHODS AND MATERIALS: We identified patients from 5 radiation oncology centers, treated with palliative RT and either pembrolizumab or nivolumab with non-small cell lung cancer, metastatic melanoma, and renal cell carcinoma. Patients who received intervening cytotoxic chemotherapy were excluded. We recorded absolute lymphocyte count (ALC) and neutrophil-to-lymphocyte ratio before and after palliative RT and at the start of ICI. Survival was analyzed using the Kaplan-Meier method and Cox proportional hazard models. RESULTS: One hundred ten patients received 225 courses of palliative RT. Median change in ALC after RT was -161 cells/mL. Decreases in ALC were greater with RT to the spine, lung/mediastinum, and chest wall compared with the brain, extremity, or abdomen/pelvis (P = .002) and after courses >5 fractions (P = .003). Extracranial and >5-fraction RT was associated with increased odds of severe lymphopenia (ALC <500) at the end of RT (odds ratio [OR], 3.7; P = .001; and OR, 3.9; P = .001, respectively). Patients who developed RT-induced severe lymphopenia were more likely to have severe lymphopenia when ICI was initiated (OR, 6.4; P = .0001), particularly when RT was administered in the previous 3 months (OR, 189; P < .0001). Severe lymphopenia at onset of ICI therapy was associated with increased mortality on multivariable analysis (hazard ratio, 2.1; P = .03). CONCLUSIONS: Extracranial or prolonged courses of RT increase the risk of severe lymphopenia, which is associated with poorer survival in patients treated with ICI.
引用
- Pike LRG, Bang A, Mahal BA, et al. The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors. Int J Radiat Oncol Biol Phys. 2018. PMID: 30227198. doi:10.1016/j.ijrobp.2018.09.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。